7-Chlor-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin

Medazepam

HCID 4041CAS 2898-12-6

Grundinformationen

Standard-SMILES
CN1CCN=C(c2ccccc2)c2cc(Cl)ccc21
InChIKey
YLCXGBZIZBEVPZ-UHFFFAOYSA-N
Summenformel
C16H15ClN2
Durchschnittliche Molmasse
270,75 g/mol
Monoisotopische Masse
270,09237616

Überblick

Medazepam is an organic molecular entity.

Namen und Bezeichner

Bevorzugter Name
Medazepam
IUPAC
7-chloro-1-methyl-5-phenyl-2,3-dihydro-1,4-benzodiazepine
Lokaler Name
7-Chlor-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin
Englischer Name
MEDAZEPAM
Summenformel
C16H15ClN2
Molmasse
270.76

Namen und Synonyme

medazepamPamnace2898-12-6MedazepamumDTXSID1048708P0J3387W3SDTXCID80286347-Chloro-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepineRefChem:810832N05BA03Ro 54556Ro 5 4556
Weitere Namen anzeigen
SimanDiepinElbrusEsmailAnsilanmezapamMezepan
220-783-4ResmitNobriumRudotelEnobrinNiveltonNarsis7-Chloro-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepine

Datenbank-Bezeichner

CAS
2898-12-6
PubChem CID
4041
DTXSID
DTXSID1048708
ChEMBL
CHEMBL28333
ChEBI
CHEBI:31807
UNII
P0J3387W3S
EC Number
220-783-4
Nikkaji
J2.167I

Eigenschaften

Berechnete Struktureigenschaften

XLogP
4,4
Polarare Oberfläche (TPSA)
15,6 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
2
Frei drehbare Bindungen
1
Schwere Atome
19

Experimentelle und physikochemische Eigenschaften

Drugs · 5 Einträge

DEA NFLIS-Drug Category -> Benzodiazepines

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals

Pharmaceuticals -> Benzodiazepines

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

SpringerMaterials PropertiesFusion temperature
Human DrugsPharmaceuticals
Collision Cross Section160.8 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physikochemische Eigenschaften

Schmelzpunkt
95 · 95-97°
Siedepunkt
420.36 °C · 420.36°C (rough estimate)
Dichte
1.1336 · 1.1336 (rough estimate)
Brechungsindex
1.5749 · 1.5749 (estimate)
storage temp.
-20 °C · -20°C
Löslichkeit
Methanol (Slightly), Water (Slightly)

Sicherheit und Regulatorisches

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P261, P263, P264, P270, P271, P280, P301+P317, P304+P340, P318, P319, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 31 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationDEA schedule IV controlled substance
Other Safety InformationIMAP assessments - 1H-1,4-Benzodiazepine, 7-chloro-2,3-dihydro-1-methyl-5-phenyl-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

Treatment · 1 Eintrag

General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended.

Toxicity Summary · 1 Eintrag

Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Sicherheitsdaten

wgk
WGK 2
ridadr
3249
risk_code
22
Toxizität
LD50 in mice (mg/kg): 360 i.p., 1070 orally (Randall)
hazard_code
Xn
hazard_class
6.1(b)

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

N - Nervous system

QN - Nervous system

MeSH Pharmacological Classification · 5 Einträge

Drugs used to prevent SEIZURES or reduce their severity.

Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.

A heterogeneous group of drugs used to produce muscle relaxation, excepting the neuromuscular blocking agents. They have their primary clinical and therapeutic uses in the treatment of muscle spasm and immobility associated with strains, sprains, and injuries of the back and, to a lesser degree, injuries to the neck. They have been used also for the treatment of a variety of clinical conditions that have in common only the presence of skeletal muscle hyperactivity, for example, the muscle spasms that can occur in MULTIPLE SCLEROSIS. (From Smith and Reynard, Textbook of Pharmacology, 1991, p358)

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.

Verwendung und Herstellung

Use ClassificationPharmaceuticals

Anwendungen

VerwendenTranquilizer (minor).

Zugehörige Reaktionen

6

Verknüpfte Notizen

Wird geladen…